An official website of the United States government.

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Treatment of Congenital Toxoplasmosis

Investigators
McLeod, Rima
Institutions
University of Chicago
Start date
1994
End date
2005
Objective
Long-term objectives are to reduce morbidity and mortality due to congenital Toxoplasma gondii infection by improved use of antimicrobial agents and understanding its pathogenesis. Our specific aim is to determine optimal methods to evaluate, treat and provide follow up care for children suffering from congenital toxoplasmosis.
More information
Our ongoing, prospective, randomized treatment trial will be continued, as initially planned, to determine early and long term outcome for treated children, including children who have been treated in utero. Cognitive, motor, ocular and audiologic outcome will be determined following treatment with one of two dosages of pyrimethamine plus sulfadiazine during the first year of life. Evaluation of the cohort of older, untreated "historical patient" children with retinal disease provides an ideal and well characterized group of patients for a future randomized, placebo-controlled study of effect of antimicrobial agents active against encysted bradyzoites on relapsing chorioretinitis. These studies will contribute to determining how to best provide medical care to children afflicted with congenital toxoplasmosis.
Funding Source
Nat'l. Inst. of Allergy and Infectious Diseases
Project number
2R01AI027530-13A2
Categories
Toxoplasma